Evidence map›Paper›PMID 16595077›Full record

ReviewHuman genomics2006

Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family.

Vasilis Vasiliou, David Ross, Daniel W Nebert

Open access · goldAbstract readReview
In one paragraph

Review in Human genomics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Association between NQO1 C609T polymorphism and colorectal cancer risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Pooled it
  2. Association between NQO1 C609T polymorphism and bladder cancer susceptibility: a systemic review and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Protective Effect of Peptides fromAntioxidants (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. SAR of Novel 3-Arylisoquinolinones:Journal of medicinal chemistry · 2022
    Article
  13. Article
  14. The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells.Journal of environmental science and health. Part C, Toxicology and carcinogenesis · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Empowering Melatonin Therapeutics withDiseases (Basel, Switzerland) · 2021
    Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Vasilis VasiliouDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA. vasilis.vasiliou@uchsc.edu
David Ross
Daniel W Nebert
University of Colorado Health · USUniversity of Cincinnati Medical Center · US

Funding

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI YADAV, JAGJIT S · 1992 to 2022
$35.4M
Role and Molecular Mechanisms of Corneal Aldehyde DehydrogenaseR01EY011490 · NEI · YALE UNIVERSITY · PI VASILIOU, VASILIS · 2004 to 2013
$4.0M
NQO1 in Protection Against Benzene ToxicicityR01ES009554 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI ROSS, DAVID · 1998 to 2007
$1.7M
NEI NIH HHS R01 EY11490NIEHS NIH HHS P30 ES06096NIEHS NIH HHS R01 ES09554
6 · The paper itself

Abstract

The NAD(P)H:quinone acceptor oxidoreductase (NQO) gene family belongs to the flavoprotein clan and, in the human genome, consists of two genes (NQO1 and NQO2). These two genes encode cytosolic flavoenzymes that catalyse the beneficial two-electron reduction of quinones to hydroquinones. This reaction prevents the unwanted one-electron reduction of quinones by other quinone reductases; one-electron reduction results in the formation of reactive oxygen species, generated by redox cycling of semiquinones in the presence of molecular oxygen. Both the mammalian NQO1 and NQO2 genes are upregulated as a part of the oxidative stress response and are inexplicably overexpressed in particular types of tumours. A non-synonymous mutation in the NQO1 gene, leading to absence of enzyme activity, has been associated with an increased risk of myeloid leukaemia and other types of blood dyscrasia in workers exposed to benzene. NQO2 has a melatonin-binding site, which may explain the anti-oxidant role of melatonin. An ancient NQO3 subfamily exists in eubacteria and the authors suggest that there should be additional divisions of the NQO family to include the NQO4 subfamily in fungi and NQO5 subfamily in archaebacteria. Interestingly, no NQO genes could be identified in the worm, fly, sea squirt or plants; because these taxa carry quinone reductases capable of one- and two-electron reductions, there has been either convergent evolution or redundancy to account for the appearance of these enzyme functions whenever they have been needed during evolution.

Indexed as

Multigene FamilyAnimalsDihydrolipoamide DehydrogenaseEvolution, MolecularFlavoproteinsGenetic VariationHumansNAD(P)H Dehydrogenase (Quinone)NADPH OxidasesNitric Oxide SynthaseDihydrolipoamide DehydrogenaseFlavoproteinsNAD(P)H Dehydrogenase (Quinone)NADPH OxidasesNitric Oxide Synthase

Identifiers

PMID16595077
PMCPMC3500182
OpenAlexW2112252275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.